logo
The Scientific Literature Can't Save Us Now

The Scientific Literature Can't Save Us Now

The Atlantic13-02-2025

Twice during his Senate confirmation hearings at the end of January, Robert F. Kennedy Jr. brought up a peer-reviewed study by a certain 'Mawson' that had come out just the week before. 'That article is by Mawson,' he said to Senator Bill Cassidy, then spelled out the author's name for emphasis: 'M-A-W-S-O-N.' And to Bernie Sanders: 'Look at the Mawson study, Senator. … Mawson. Just look at that study.'
'Mawson' is Anthony Mawson, an epidemiologist and former academic who has published several papers alleging a connection between childhood vaccines and autism. (Any such connection has been thoroughly debunked.) His latest on the subject, and the one to which Kennedy was referring appeared in a journal that is not indexed by the National Library of Medicine, or by any other organization that might provide it with some scientific credibility. One leading member of the journal's editorial board, a stubborn advocate for using hydroxychloroquine and ivermectin to treat COVID-19, has lost five papers to retraction. Another member is Didier Raoult (whose name the journal has misspelled), a presence on the Retraction Watch leaderboard, which is derived from the work of a nonprofit we cofounded, with 31 retractions. A third, and the journal's editor in chief, is James Lyons-Weiler, who has one retraction of his own and has called himself, in a since deleted post on X, a friend and 'close adviser to Bobby Kennedy.' (Mawson told us he chose this journal because several mainstream ones had rejected his manuscript without review. Lyons-Weiler did not respond to a request for comment.)
Perhaps a scientist or politician—and certainly a citizen-activist who hopes to be the nation's leading health-policy official—should be wary of citing anything from this researcher or this journal to support a claim. The fact that one can do so anyway in a setting of the highest stakes, while stating truthfully that the work originated in a peer-reviewed, academic publication, reveals an awkward fact: The scientific literature is an essential ocean of knowledge, in which floats an alarming amount of junk. Think of the Great Pacific Garbage Patch, but the trash cannot be identified without special knowledge and equipment. And while this problem is long-standing, until the past decade or so, no one with both the necessary expertise and the power to intervene has been inclined to help. With the Trump administration taking control of the CDC and other posts on the nation's science bulwark, the consequences are getting worse. As RFK Jr. made plain during his confirmation hearing, the advocates or foes of virtually any claim can point to published work and say, 'See? Science!'
This state of affairs is not terribly surprising when one considers how many studies labeled as 'peer reviewed' appear every year: at least 3 million. The system of scientific publishing is, as others have noted, under severe strain. Junk papers proliferate at vanity journals and legitimate ones alike, due in part to the 'publish or perish' ethos that pervades the research enterprise, and in part to the catastrophic business model that has captured much of scientific publishing since the early 2000s.
That model—based on a well-meaning attempt to free scientific findings from subscription paywalls—relies on what are known as article-processing charges: fees researchers pay to publishers. The charges aren't inconsequential, sometimes running into the low five figures. And the more papers that journals publish, the more money they bring in. Researchers are solicited to feed the beast with an ever-increasing number of manuscripts, while publishers have reason to create new journals that may end up serving as a destination for lower-quality work. The result: Far too many papers appear each year in too many journals without adequate peer review or even editing.
The mess that this creates, in the form of unreliable research, can to some extent be cleaned up after publication. Indeed, the retraction rate in science—meaning the frequency with which a journal says, for one reason or another, 'Don't rely on this paper'—has been growing rapidly. It's going up even faster than the rate of publication, having increased roughly tenfold over the past decade. That may sound like editors are weeding out the literature more aggressively as it expands. And the news is in some ways good—but even now, far more papers should be retracted than are retracted. No one likes to admit an error—not scientists, not publishers, not universities, not funders.
Profit motive can sometimes trump quality control even at the world's largest publishers, which earn billions annually. It also fuels a ravenous pack of 'paper mills' that publish scientific work with barely any standards whatsoever, including those that might be used to screen out AI-generated scientific slop.
An empiricist might say that the sum total of these articles simply adds to human knowledge. If only. Many, or even most, published papers serve no purpose whatsoever. They simply appear and … that's it. No one ever cites them in subsequent work; they leave virtually no trace of their existence.
Until, of course, someone convinces a gullible public—or a U.S. senator—that all research currency, new and old, is created equal. Want to make the case that childhood vaccines cause autism? Find a paper in a journal that says as much and, more important, ignore the countless other articles discrediting the same idea. Consumers are already all too familiar with this strategy: News outlets use the same tactic when they tell you that chocolate, coffee, and red wine are good for you one week—but will kill you the next.
Scientists are not immune from picking and choosing, either. They may, for example, assert that there is no evidence for a claim even though such evidence exists—a practice that has been termed ' dismissive citation.' Or they may cite retracted papers, either because they didn't bother checking on those papers' status or because that status was unclear. (Our team built and shared the Retraction Watch Database —recently acquired by another nonprofit—to help address the latter problem.)
The pharmaceutical industry can also play the science-publication system to its advantage. Today, reviewers at the FDA rely on raw data for their drug approvals, not the questionable thumbs-up of journals' peer review. But if the agency, flawed as it may be, has its power or its workforce curbed, the scientific literature (with even greater flaws) is not prepared to fill the gap.
Kennedy has endorsed at least one idea that could help to solve these many problems. At his confirmation hearing, he suggested that scientific papers should be published alongside their peer reviews. (By convention, these appraisals are kept both anonymous and secret.) A few publishers have already taken this step, and while only time will tell if it succeeds, the practice does appear to blunt the argument that too much scientific work is hashed out behind closed doors. If such a policy were applied across the literature, we might all be better off.
Regardless, publishers must be more honest about their limitations, and the fact that many of their papers are unreliable. If they did their part to clean up the literature by retracting more unworthy papers, even better. Opening up science at various stages to more aggressive scrutiny—' red teaming,' if you will—would also help. Any such reforms will be slow-moving, though, and America is foundering right now in a whirlpool of contested facts. The scientific literature is not equipped to bail us out.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

New York legislature passes medical aid in dying bill
New York legislature passes medical aid in dying bill

Yahoo

time18 minutes ago

  • Yahoo

New York legislature passes medical aid in dying bill

Jun. 10—ALBANY — The New York state legislature has passed a bill to legalize physician-assisted suicide, a program supporters are calling "medical aid in dying." On Monday evening, with just a few days left for voting for the scheduled legislative session, the state Senate voted to pass its copy of the legislation. The state Assembly passed it earlier this year, and the bill now awaits Gov. Kathleen C. Hochul's decision to sign, veto or amend the legislation. Under the terms of the bill, people with a terminal illness who have an estimated six months or less before their disease will kill them can ask their physician for a prescription for life-ending drugs, which they can take home and consume on their own. The legislation has some protections, requiring a physician to evaluate the patient's ability to make decisions and refer them for psychiatric evaluation if there are questions over capacity. Patients have to make an oral and written request for the life-ending drugs, and the request be witnessed by two adults who are not closely related to the patient or likely to benefit after their death. It also permits medical professionals to recuse themselves from requests for medically assisted suicide, ordering them to refer requests they refuse to other doctors. Supporters of the bill say it will give New Yorkers suffering from terminal illnesses a safe, humane way to end their lives. They point to cases where terminally ill people have chosen to stop eating or drinking or chosen to end their lives in other, not legally sanctioned ways. Opponents of the bill raise concerns over the message it sends to sick people, that they should choose death rather than fight for their health, as well as practical concerns over whether the medication that would be prescribed could be a health hazard if not properly stored. They also expressed concerns over the bill's approach to how the death will be recorded. Under the bill's terms, someone who takes advantage of the program would have their cause of death listed as their terminal illness, not the ingestion of life-ending drugs. They also raised concerns over the lack of post-dispensation tracking for the lethal drugs, raising concerns they could be misused. The bill has circulated in Albany for nearly a decade, going most years without a floor vote in either chamber. Just last year, it lacked majority support in the Senate, but a successful lobbying effort this year pushed it to approval in the Assembly and now in the Senate. Debate stretched into Monday evening, with detractors in the Senate expressing concern. Sen. Steven D. Rhoads, R-Nassau, questioned why the bill doesn't include a specific requirement that doctors review a patient's medical records before prescribing the medication. "There is nothing in the bill that requires that," he said during floor debate. But proponents of the bill said it's a meaningful step towards medical autonomy and the right to choose — Senator Brad Hoylman-Sigal, D-Manhattan, the Senate sponsor of the bill, said that some identified gaps in the bill will be filled in the regulation-crafting process with the state Department of Health, which will be tasked with overseeing the implementation and authorization necessary to allow New York doctors and pharmacies to dispense these lethal medications. The lobbying isn't over yet. A major opponent of the bill, the New York State Catholic Conference, took to the halls of the Capitol on Monday in a last-ditch effort to kill the bill's chances in the Senate. Their effort was unsuccessful, but they've continued to push the governor to reject the bill. Sen. Mark C. Walczyk, R-Sackets Harbor, said in a statement that he was sad to see the bill pass. "I have tremendous sympathy for those with terminal illnesses and respect families who face end-of-life decisions," Walczyk said in a statement. "This legislation lacks critical protections for the vulnerable, structurally incentivizes suicide, and devalues human life. We need only look at the examples of states and nations that have promoted this policy. Instead of providing an option for individuals to end their lives, we should focus on improving health care for the vulnerable and enhancing hospice and palliative care for the terminally ill to ensure that every New Yorker has access to compassionate support during their most vulnerable moments, rather than offering a misguided solution that encourages despair."

Voting rights, access bills stopped in the Alabama Legislature
Voting rights, access bills stopped in the Alabama Legislature

Yahoo

time18 minutes ago

  • Yahoo

Voting rights, access bills stopped in the Alabama Legislature

Rep. Thomas Jackson, D-Thomasville (right, at lectern) raises his hand during a debate in the Alabama House of Representatives on March 6, 2025 at the Alabama Statehouse in Montgomery, Alabama. Jackson filed an early voting bill this session, which was not considered by a committee, along with other voting-related bills. (Brian Lyman/Alabama Reflector) A collection of bills aimed to enhance voting access in Alabama were never considered by committees during the 2025 legislative session, but advocates say the fight for enhanced voting rights in Alabama is not over HB 59, sponsored by Rep. Thomas Jackson, D-Thomasville, would have required one early voting precinct in each county for one week before Election Day. According to a study by the Center for Election Innovation and Research (CEIR), about 70% of the ballots cast nationwide in 2020 were cast before Election Day, and 40% were cast before Election Day in 2016. In 2016, 25% of ballots nationwide were cast through early in-person voting, of the states that offer the option, according to the study. 'Senior citizens really brought it to my attention,' Jackson said in an interview on Monday. 'So I drafted it, and I put it the simplest way that I could do it: a week out before the election, four days prior to the elections, and nobody liked that. Republicans don't like that.' Alabama does not allow early voting and does not have no-excuse absentee voting. Amid the COVID pandemic in 2020, state leaders effectively allowed anyone to cast an absentee ballot, but that was rescinded after the election. The League of Women Voters of Alabama supported the measures. Kim Bailey, president of the league, said in an interview Thursday that the bills would expand access to voting in Alabama, which would increase voter turnout in the state. 'You can make a plan, but if something comes up on voting day, you may not be able to get to the ballot box,' Bailey said. 'Voting as a right and not a privilege. I think that's important that they'd be able to exercise that right.' In 2024, there were 3.7 million people registered to vote in Alabama, according to the Secretary of State's website. But only 2.2 million (59%) people voted in the 2024 Presidential election. That was significantly less than the national voter turnout of 88% in 2024, according to the U.S. Census Bureau, and the lowest percentage of Alabama voters to cast ballots in a presidential election since 1988. The bill was assigned to the House Constitution, Campaigns and Elections Committee, but Rep. Bob Fincher, R-Woodland, chair of the committee, said he did not take HB 59 up in his committee because he is not in favor of early voting due to the cost to the state. 'It costs the state extra money when you vote early,' he said. 'If there's a change in the campaign, you cannot go back and change your vote.' The Legislative Services Agency did not provide a fiscal note for any of the election access related bills. Although a total cost is not available, Bailey said early voting would utilize state employees that are already working and would be held at locations that are already staffed. 'That wouldn't require a lot of infrastructure cost in those kinds of things, so depending on what the legislation that passes the cost could be not really very much,' Bailey said. Jackson said the potential cost to the state for a week of early voting would be much less than the cost to the state for unconstitutional bills and the congressional redistricting trial. In the state's General Fund budget, a $300,000 line item was added for 'reapportionment litigation fees.' 'We don't have an idea of the cost to the state. Look at all these lawsuits, these millions of dollars that are being paid to lawyers for these unconstitutional bills. That's a cost to the state,' Jackson said. 'See, they can come up with any excuse when they don't want something.' Jerome Dees, the Alabama policy director at the Southern Poverty Law Center, said in an interview Thursday that he was not surprised the bills were not considered. He said the state has been regressing in voting access and inclusivity for the last decade. 'This bill is really kind of an effort to try and present a new vision of what democracy can and should be in Alabama, which is kind of the home of the civil rights movement,' Dees said. In fact, Dees said the state's congressional redistricting trial has highlighted the need for more voter protections and access. 'The fact that not a single one of these bills that aimed to expand voter access to create oversight over the redistricting process, whether that's at the municipal level, drawing of city council districts or at the state and federal level,' Dees said. 'According to the federal courts, is obviously a problem, just based on recent rulings. The fact that the Legislature intentionally chose not to touch any of those, I think, is as telling as anything.' In 2021, the Alabama Legislature approved congressional district maps that were later challenged in court and struck down in 2022 by a three-judge panel, which ordered the districts to be redrawn. In 2023, the Legislature redrew the maps, which were again challenged by plaintiffs for not meeting the court's requirement of allowing Black voters to elect a candidate of their choice in a second district. The court struck down the 2023 map passed by the Legislature and appointed a special master to submit three potential remedial maps in time for the 2024 election. The Alabama Attorney General's Office said last month the state may forgo drawing new congressional district maps before 2030 to prevent federal oversight of future redistricting, pausing the redistricting for five years. HB 97, sponsored by Rep. Kenyatté Hassell, D-Montgomery, would have allowed voters to cure their absentee ballot affidavit if they submit them before the election and the absentee election manager finds an error. Currently, the ballots are set aside and not counted if election officials find a defect with the affidavits. Hassell said in an interview on Wednesday that the bill would have given absentee voters a better chance for their ballot to be counted. 'People were making mistakes on their ballots, and even though they didn't know they made mistakes,' he said. 'We might have people who voted on an absentee ballot for the last 20 years, and their vote never counted because they made the same mistake over and over again not knowing they made that mistake.' The bill was assigned to Fincher's committee, but Fincher said he did not take it up because of conversations with Hassell and the Secretary of State Wes Allen. 'I've been very clear, I believe in Election Day, not Election month,' Allen said in a statement Monday. Hassell raised concerns that the executive branch had control over what bills did or did not get taken up in committee. 'When one person in the executive branch has an agenda, that shouldn't dictate if we all feel like this is a good piece of legislation that'll help the citizens,' Hassell said. 'That's why we have a House. That's why we have a Senate.' HB 31, sponsored by Rep. Adline Clarke, D-Mobile, allows people with a disability, or those unable to read or write, to designate someone to assist them with delivering an absentee ballot application or the absentee ballot itself, to the election manager. Messages seeking comment from Clarke were left Wednesday and Monday. Dees and Bailey expect the bills to be filed again for the 2026 Legislative Session. 'We're going to keep filing this year, I'm gonna keep filing until something happens,' Jackson said. 'We just have to keep hitting that rock until they crack. That's why I'm still pushing it, because it's the right thing to do, and the people of the state want it.'

Tesla could lose billions in revenue as Trump administration weighs eliminating a key regulatory credit loophole
Tesla could lose billions in revenue as Trump administration weighs eliminating a key regulatory credit loophole

Yahoo

time24 minutes ago

  • Yahoo

Tesla could lose billions in revenue as Trump administration weighs eliminating a key regulatory credit loophole

Senate Republicans are proposing the elimination of penalties for not abiding by certain fuel efficiency standards. These penalties would render regulatory credits, an incentive for auto companies to abide by the standards, essentially useless. Tesla relies on these credits for a chunk of its revenue, racking up $2.67 billion from them in 2024. As Tesla stock sputters following CEO Elon Musk's feud with President Donald Trump, the EV maker is facing yet another threat from the administration. Republicans are doubling down on efforts to weaken carbon emission standards for the auto industry, which have provided opportunities for companies producing eco-friendly vehicles, such as Tesla, to receive and sell regulatory credits for profit. The Senate Committee on Commerce, Science, and Transportation proposed last week eliminating penalties for companies not meeting certain economy fuel standards set to mitigate carbon emissions. The proposal is included in the committee's portion of Trump's sweeping budget bill. After Corporate Average Fuel Economy (CAFE) standards were introduced in 1975 as a means of setting standards for fuel efficiency, a credits program emerged following lobbying efforts from auto companies looking to be paid to produce lower emission vehicles. Auto companies that produce a certain amount of energy-efficient cars are given a number of credits, depending on how eco-friendly their manufactured vehicles are. Companies are required to have a certain number of credits annually. While Tesla is able to easily attain these credits as a producer of cars that don't run on gas, other manufacturers, like Ford and Stellantis, are not. Therefore, they buy credits from Tesla, who can sell those credits for practically 100% profit. The Senate committee's proposal would eliminate certain CAFE penalties, rendering the need to have credits useless, Chris Harto, senior policy analyst at Consumer Reports, told Fortune in an email. 'It also would essentially turn the CAFE standards into nothing more than a reporting requirement with no consequences for automakers who fail to improve the efficiency of the vehicles they sell,' he said. The committee argued the provision would 'modestly' bring down the cost of cars by eliminating CAFE penalties. These CAFE credits have been a boon for Tesla, which has been battered by CEO Musk's controversial involvement in—and departure from—the Trump administration. The EV-maker made $2.76 billion from regulatory credits in fiscal 2024 and $595 million in the first quarter of 2025, according to earnings reports. Tesla reported $420 million in net income the same quarter, meaning without the regulatory credit, the company would not have been profitable. 'A key element of Tesla's profitability has been its ability to generate credits because it makes zero emissions, and sell those credits to more polluting car companies like GM and Ford and Stellantis—primarily gas-guzzlers that don't really want to make clean cars,' Dan Becker, director of the Safe Climate Transport Campaign at the Center for Biological Diversity, told Fortune. 'By taking away these credits, they're taking away a key element of Tesla's profitability,' he added. Tesla did not respond to Fortune's request for comment. The Senate committee's proposal is one of several efforts by the Trump administration to cut auto sustainability standards. Last month the Senate passed legislation blocking a California effort to ban gas-powered vehicles and mandate sales of only zero-emission cars and light trucks by 2035. The bill, should it be signed by the president, would take a $2 billion bite out of Tesla's revenue, according to JPMorgan analysts. Also in Trump's massive budget bill is the elimination at the end of this year of tax credits up to $7,500 for buyers of certain Tesla and other EV models, which would cost $1.2 billion of Tesla's full-year profit, the analysts calculated. Tesla's credit headaches extend across the Atlantic Ocean. Regulatory credits are common in Europe and Asia, and the European Union, for example, gives credits to European automakers who sell a certain number of zero-emission cars. But as Tesla sales crater overseas—including falling by 49% in April—the EV maker may not be able to reach the number of sales necessary to gain credits. As of April, Tesla—grouped with Ford and Stellantis in a manufacturing pool to achieve the EU's emission standards—are still short of the target, according to a report from the International Council on Clean Transportation. Poor sales could jeopardize Tesla's ability to rack up credits. 'If things go bad for Tesla and they don't sell enough cars this year, they might not have enough credits for what they promised Stellantis and the others,' ICCT managing director Peter Mock told Politico in March. 'Tesla is under pressure.' This story was originally featured on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store